https://www.socictopen.socict.org/files/original/5ba645e9c9596e93e1bcb15c8a2094e2.pdf c9ec681ab70854644dd99ebac0d8b068 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS Creator An entity primarily responsible for making the resource Claudio Ucciferri, Barone Mirko, Jacopo Vecchiet, Katia Falasca Description An account of the resource Background and purpose: Currently clinicians wide world are facing with SARS-CoV-2 pandemy, whose clinical features include fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) which can progress to life threatening sequelae. Aim of this study is to evaluate both efficacy and safety of pidotimod in paucisymptomatic SARS-CoV-2 patients without any evidence of concurrent pneumonia. Methods: Twenty SARS-CoV-2 1:1 allocated (pidotimod vs symptomatic therapy) Brescia-COVID Respiratory Severity Scale 0 patients were enrolled and complaining fever, cough without any sign of respiratory failure. None of them required standard regimens or hospitalization. Results: At two-brace cohort analysis no significant selection bias between groups were reported. In the absence of relevant drug-induced side effects or disease progression during therapy, the experimental group presented an earlier clinical resolution than the control one (Group A vs Group B: 4.10±2.18 vs 7.50±2.63 days; 95%CI: 1.13 – 5.67, SE: 1.08; p=0.006), as confirmed from a linear regression analysis. Conclusions:  Pidotimod regimens in selected SARS-COV2 patients could be a viable option to induce symptoms regression, as an earlier defervescence protects from the indolent course of cytokine cascade activation. Rebalancing the immune status with pidotimod may also have prevented the evolution of the infection in patients. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Safety, covid-19, treatment, Immunomodulatory Identifier An unambiguous reference to the resource within a given context 10.4084/mjhid.2020.048 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Diseases of the blood and blood-forming organs